The study of how differences in metabolites in an individual or subset of the population might be used to predict their various responses to a medicine or medical intervention is known as pharmacometabolomics or pharmacometabonomics. The premise that an individual's metabolic profile is related to their health-to-disease status, referred to as their "metabotype," is at the centre of pharmacometabolomics. Pharmacometabolomics data can help understand different drug responses (i.e. responders vs non-responders), be used in precision medicine to determine drug dose levels or specific drugs to prescribe for an individual, provide biomarkers related to drug efficacy or toxicity effects, and, in many cases, provide pharmacokinetics information, making pharmacometabolomics useful for precision medicine. Pharmacometabolomics can be used to tailor treatment type, dose, and duration, as well as to track metabolite profiles during treatments. Existing '-omics' and health-record databases, as well as biobanks of human fluid samples and tissues, are valuable resources for pharmacometabolomics, which seeks to uncover biomarkers of therapeutic effects across the course of a disease.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Pharmacogenomics: current status and future directions
Matthias Schwab, University of Tübingen, Germany
Title : Talus bone of the hindfoot: Unique anatomy and an important clinical implication
Abdelmonem Awad Hegazy, Zarqa University, Jordan
Title : The use of anti seizure medication therapeutic blood level determination to personalise the treatment of epileptic seizures especially in patients attending the accident and emergency department
Roy Gary Beran, University of New South Wales, Australia
Title : Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
Mitra Safa, Shahid Beheshti University of Medical Sciences, Iran (Islamic Republic of)
Title : Precision Treatment of Alzheimer's
Boris Tankhilevich, Magtera, Inc., United States